



**30**  
YEARS

## Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

August 27, 2025

– Presentations to be webcast on [www.exelixis.com](http://www.exelixis.com) –

ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 27, 2025-- [Exelixis, Inc.](http://www.exelixis.com) (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September:

- 2025 Wells Fargo Healthcare Conference: Exelixis is scheduled to present at 12:45 p.m. ET / 9:45 a.m. PT on Wednesday, September 3 in Everett, MA.
- Citi's 2025 Biopharma Back to School Conference: Exelixis is scheduled to present at 3:15 p.m. ET / 12:15 p.m. PT on Wednesday, September 3 in Boston.
- Morgan Stanley 23<sup>rd</sup> Annual Global Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, September 9 in New York City.
- H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference: Exelixis is scheduled to present at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, September 10 in New York City.
- Bernstein's 2<sup>nd</sup> Annual Healthcare Forum: Exelixis is scheduled to present at 8:50 a.m. ET / 5:50 a.m. PT on Wednesday, September 24 in New York City.

To access the webcast links, log onto [www.exelixis.com](http://www.exelixis.com) and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days.

### About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules and biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETRYX<sup>®</sup> (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit [www.exelixis.com](http://www.exelixis.com), follow [@ExelixisInc](https://twitter.com/ExelixisInc) on X (Twitter), like [Exelixis, Inc.](https://www.facebook.com/Exelixis,Inc) on Facebook and follow [Exelixis](https://www.linkedin.com/company/exelixis) on LinkedIn.

*Exelixis, the Exelixis logo and CABOMETRYX are registered U.S. trademarks.*

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250827463554/en/): <https://www.businesswire.com/news/home/20250827463554/en/>

### Investors Contact:

Varant Shirvanian  
Director, Investor Relations  
Exelixis, Inc.  
650-837-7917  
[vshirvanian@exelixis.com](mailto:vshirvanian@exelixis.com)

### Media Contact:

Hal Mackins  
For Exelixis, Inc.  
415-994-0040  
[hal@torchcommunications.com](mailto:hal@torchcommunications.com)

Source: Exelixis, Inc.